Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24697160 | 0.92 | IKBKE (0.30) | TSHRCYP3A4MAPK1IKBKETBK1 | |
| SCHEMBL23012643 | 0.85 | IKBKE (0.32) | IKBKETBK1 | |
| SCHEMBL19346345 | 0.83 | CYP3A4 (0.46) | TSHRCYP3A4MAPK1CD44 | |
| SCHEMBL18609035 | 0.81 | TSHR (0.36) | TSHR | |
| SCHEMBL21729549 | 0.79 | SLC6A2 (0.33) | TSHRCYP3A4MAPK1SLC6A2SLC6A4 | |
| SCHEMBL937859 | 0.76 | KEAP1 (0.50) | CYP3A4CYP1A2 | |
| SCHEMBL20681154 | 0.74 | FADS1 (0.33) | SLC6A4CD44 | |
| SCHEMBL24800954 | 0.74 | — | — | |
| SCHEMBL18618399 | 0.73 | HDAC1 (0.33) | — | |
| SCHEMBL405476 | 0.73 | CD44 (0.48) | TSHRCYP3A4MAPK1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106288-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| EP-3344599-B1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020035466-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106288-A1 | NOVEL SULFONEUREA COMPOUNDS | NLRP3, NLRP1, PYCARD | TSHR 3120/4885CYP3A4 139/4885MAPK1 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.